China Resources Pharmaceutical Group Limited (HKG: 3320)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
5.43
-0.03 (-0.55%)
Dec 20, 2024, 4:08 PM HKT

China Resources Pharmaceutical Group Statistics

Total Valuation

China Resources Pharmaceutical Group has a market cap or net worth of HKD 34.11 billion. The enterprise value is 132.80 billion.

Market Cap 34.11B
Enterprise Value 132.80B

Important Dates

The last earnings date was Friday, November 29, 2024.

Earnings Date Nov 29, 2024
Ex-Dividend Date Sep 10, 2024

Share Statistics

China Resources Pharmaceutical Group has 6.28 billion shares outstanding.

Current Share Class n/a
Shares Outstanding 6.28B
Shares Change (YoY) n/a
Shares Change (QoQ) n/a
Owned by Insiders (%) 0.01%
Owned by Institutions (%) 7.97%
Float 1.82B

Valuation Ratios

The trailing PE ratio is 8.51 and the forward PE ratio is 6.94. China Resources Pharmaceutical Group's PEG ratio is 0.94.

PE Ratio 8.51
Forward PE 6.94
PS Ratio 0.13
PB Ratio 0.66
P/TBV Ratio 1.67
P/FCF Ratio 2.00
P/OCF Ratio n/a
PEG Ratio 0.94
Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 8.12, with an EV/FCF ratio of 7.80.

EV / Earnings 32.72
EV / Sales 0.49
EV / EBITDA 8.12
EV / EBIT 10.33
EV / FCF 7.80

Financial Position

The company has a current ratio of 1.37, with a Debt / Equity ratio of 0.78.

Current Ratio 1.37
Quick Ratio 1.02
Debt / Equity 0.78
Debt / EBITDA 5.14
Debt / FCF 4.80
Interest Coverage 5.47

Financial Efficiency

Return on equity (ROE) is 8.94% and return on invested capital (ROIC) is 4.32%.

Return on Equity (ROE) 8.94%
Return on Assets (ROA) 2.78%
Return on Capital (ROIC) 4.32%
Revenue Per Employee 3.70M
Profits Per Employee 55,780
Employee Count 72,986
Asset Turnover 0.97
Inventory Turnover 6.09

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has increased by +15.29% in the last 52 weeks. The beta is 0.39, so China Resources Pharmaceutical Group's price volatility has been lower than the market average.

Beta (5Y) 0.39
52-Week Price Change +15.29%
50-Day Moving Average 5.51
200-Day Moving Average 5.47
Relative Strength Index (RSI) 50.82
Average Volume (20 Days) 9,154,730

Short Selling Information

Short Interest n/a
Short Previous Month n/a
Short % of Shares Out n/a
Short % of Float n/a
Short Ratio (days to cover) n/a

Income Statement

In the last 12 months, China Resources Pharmaceutical Group had revenue of HKD 269.14 billion and earned 4.06 billion in profits. Earnings per share was 0.64.

Revenue 269.14B
Gross Profit 42.45B
Operating Income 12.42B
Pretax Income 11.44B
Net Income 4.06B
EBITDA 15.25B
EBIT 12.42B
Earnings Per Share (EPS) 0.64
Full Income Statement

Balance Sheet

The company has 35.54 billion in cash and 81.84 billion in debt, giving a net cash position of -46.30 billion or -7.37 per share.

Cash & Cash Equivalents 35.54B
Total Debt 81.84B
Net Cash -46.30B
Net Cash Per Share -7.37
Equity (Book Value) 104.35B
Book Value Per Share 8.27
Working Capital 57.61B
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 19.66 billion and capital expenditures -2.63 billion, giving a free cash flow of 17.03 billion.

Operating Cash Flow 19.66B
Capital Expenditures -2.63B
Free Cash Flow 17.03B
FCF Per Share 2.71
Full Cash Flow Statement

Margins

Gross margin is 15.77%, with operating and profit margins of 4.61% and 1.51%.

Gross Margin 15.77%
Operating Margin 4.61%
Pretax Margin 4.25%
Profit Margin 1.51%
EBITDA Margin 5.67%
EBIT Margin 4.61%
FCF Margin 6.33%

Dividends & Yields

This stock pays an annual dividend of 0.18, which amounts to a dividend yield of 3.26%.

Dividend Per Share 0.18
Dividend Yield 3.26%
Dividend Growth (YoY) n/a
Years of Dividend Growth 3
Payout Ratio 23.30%
Buyback Yield n/a
Shareholder Yield 3.26%
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

China Resources Pharmaceutical Group has an Altman Z-Score of 1.6. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score 1.6
Piotroski F-Score n/a